- Home
- CERO vs TRNR Comparison
CERO vs TRNR Comparison
Compare CERO & TRNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- TRNR
- Stock Information
- Founded
- CERO 2017
- TRNR 2017
- Country
- CERO United States
- TRNR United States
- Employees
- CERO N/A
- TRNR N/A
- Industry
- CERO
- TRNR Consumer Electronics/Appliances
- Sector
- CERO
- TRNR Technology
- Exchange
- CERO Nasdaq
- TRNR Nasdaq
- Market Cap
- CERO 5.6M
- TRNR 5.8M
- IPO Year
- CERO N/A
- TRNR 2023
- Fundamental
- Price
- CERO $5.43
- TRNR $3.41
- Analyst Decision
- CERO Strong Buy
- TRNR
- Analyst Count
- CERO 2
- TRNR 0
- Target Price
- CERO $45.00
- TRNR N/A
- AVG Volume (30 Days)
- CERO 306.0K
- TRNR 357.7K
- Earning Date
- CERO 08-22-2025
- TRNR 11-13-2025
- Dividend Yield
- CERO N/A
- TRNR N/A
- EPS Growth
- CERO N/A
- TRNR N/A
- EPS
- CERO N/A
- TRNR N/A
- Revenue
- CERO N/A
- TRNR $6,972,000.00
- Revenue This Year
- CERO N/A
- TRNR $578.14
- Revenue Next Year
- CERO N/A
- TRNR $130.65
- P/E Ratio
- CERO N/A
- TRNR N/A
- Revenue Growth
- CERO N/A
- TRNR 373.32
- 52 Week Low
- CERO $4.27
- TRNR $2.81
- 52 Week High
- CERO $895.40
- TRNR $345.00
- Technical
- Relative Strength Index (RSI)
- CERO 32.53
- TRNR 40.57
- Support Level
- CERO $4.27
- TRNR $2.81
- Resistance Level
- CERO $5.65
- TRNR $4.19
- Average True Range (ATR)
- CERO 0.54
- TRNR 0.49
- MACD
- CERO -0.17
- TRNR 0.05
- Stochastic Oscillator
- CERO 31.12
- TRNR 39.79
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.